Amyloidosis: Recognition, Confirmation, Prognosis, and Therapy Morie A. Gertz, M.D., Martha Q. Lacy, M.D., Angela Dispenzieri, M.D. Mayo Clinic Proceedings Volume 74, Issue 5, Pages 490-494 (May 1999) DOI: 10.4065/74.5.490 Copyright © 1999 Mayo Foundation for Medical Education and Research Terms and Conditions
Fig. 1 Serum protein electrophoresis associated with illustrative case. Note small monoclonal peak (arrow) in middle of gamma region. Mayo Clinic Proceedings 1999 74, 490-494DOI: (10.4065/74.5.490) Copyright © 1999 Mayo Foundation for Medical Education and Research Terms and Conditions
Fig. 2 Urinary protein electrophoresis associated with illustrative case. Note large spike of light chain in gamma region. Urinary total protein was only 330 mg for 24-hour period. Mayo Clinic Proceedings 1999 74, 490-494DOI: (10.4065/74.5.490) Copyright © 1999 Mayo Foundation for Medical Education and Research Terms and Conditions
Fig. 3 Distribution of serum M protein levels in patients with primary amyloidosis. Mayo Clinic Proceedings 1999 74, 490-494DOI: (10.4065/74.5.490) Copyright © 1999 Mayo Foundation for Medical Education and Research Terms and Conditions
Fig. 4 Distribution of urinary protein levels in patients withprimary amyloidosis. Mayo Clinic Proceedings 1999 74, 490-494DOI: (10.4065/74.5.490) Copyright © 1999 Mayo Foundation for Medical Education and Research Terms and Conditions